Full Press Release Details
to Participate in Upcoming Investor Conferences
BEIJING, September 2, 2014 -- Sinovac Biotech Ltd. (NASDAQ:SVA),
a leading provider of biopharmaceutical products in China, today announced that the Company's management will participate
in the following investor conferences in September:
Please contact your institutional sales representative at the
respective sponsoring bank to schedule a meeting with the Company.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company
that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval
for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program.
The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac has
filed a new drug application with the China Food & Drug Administration for its proprietary enterovirus 71 vaccine, having been
proven effective in preventing hand, foot and mouth disease in infants and children during its Phase III trial. The company is
currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides
vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring
growth opportunities in international markets. The Company has exported select vaccines to Mongolia, Nepal, the Philippines and
Mexico, and was recently granted a license to commercialize its hepatitis A vaccine in Chile. For more information, please visit
the Company's website at www.Sinovac.com .
Sinovac Biotech Ltd.
Helen Yang / Chris Lee
Tel: +86-10-8279-9659 / 9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com
Email: william.zima@icrinc.com